Teratogenicity testing in humans: a method demonstrating safety of bendectin.
We investigated the incidence of birth defects in the offspring of women who took Bendectin during pregnancy. Copies of all prescriptions issued for Bendectin in two Cities, Leeds and Liverpool, over periods of 12 and 14 months, respectively, were scanned and a record initiated for each patient. Birth notifications were later searched for matching with indexed patients. Births were traced for 2,298 patients and the incidence of major defects compared with those in the relevant populations. We found no evidence to suggest that Bendectin is teratogenic in humans.
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use / Q000633:toxicity*; D003509:Cyclohexanecarboxylic Acids / Q000633:toxicity*; D004025:Dicyclomine / Q000627:therapeutic use / Q000633:toxicity*; D004319:Doxylamine / Q000627:therapeutic use / Q000633:toxicity*; D004341:Drug Evaluation; D004622:Embryo, Mammalian / Q000187:drug effects*; D004625:Embryo, Nonmammalian; D005260:Female; D005333:Fetus / Q000187:drug effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011725:Pyridines / Q000633:toxicity*; D011736:Pyridoxine / Q000627:therapeutic use / Q000633:toxicity*; D013723:Teratogens
D000932:Antiemetics; D003509:Cyclohexanecarboxylic Acids; D011725:Pyridines; D013723:Teratogens; D004025:Dicyclomine; D004319:Doxylamine; D011736:Pyridoxine